Ocular Therapeutix prices $475M common stock offering at $12.53/share to fund AXPAXLI trials

OCULAR THERAPEUTIX, INC

Offering of 37,909,018 shares priced at $12.53 each for gross proceeds ~$475M; net proceeds ~$445.9M.
Net proceeds plus existing cash expected to fund operations into 2028, excluding full AXPAXLI commercial launch costs.
Funds to support AXPAXLI open-label extension in wet AMD, Phase 3 trials in NPDR, and manufacturing scale-up.
Offering expected to close Oct 1, 2025; BofA Securities, TD Cowen, Piper Sandler & Co. acting as joint book-runners.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.